In a spontaneous metastatic ovarian cancer mouse model (MISIIR-TAg mice), 81% of mice treated intraperitoneally with M002 were less likely to develop metastatic ovarian cancer when compared to 18% in PBS control groups, and this was associated with higher numbers of tumor antigen-specific CD8+ T-cells within the omentum and peritoneal cavity [160]. This evidence concerns the gene CD8A and neoplasm.